Citation Impact
Citing Papers
A novel anti-inflammatory natural product from Sphaeranthus indicus inhibits expression of VCAM1 and ICAM1, and slows atherosclerosis progression independent of lipid changes
2015
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
2014
COVID-19: A promising cure for the global panic
2020 Standout
Psoriasis
2021 Standout
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
2014
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
2015 Standout
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
2014 Standout
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
2011
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Etanercept for the Treatment of Rheumatoid Arthritis
2018
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Industry sponsorship and research outcome
2017 Standout
Works of Anna Jamnitski being referenced
Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
2012
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
2011
Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
2012
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
2010